Maggiore Christopher D.

Director Maggiore buys 1,766 shares of ZIVO at $8.49; 4 of 5 prior same-ticker buys achieved positive 90d returns; cluster buy underway.

Christopher D. Maggiore, a director, purchased 1,766 shares at $8.49, bringing holdings to 519,292 shares. This is the sixth buy signal in his cross-ticker track record with a 90-day win rate of 83.33%, though his specific same-ticker history shows mixed results: 4 of 5 prior ZIVO purchases were well-timed at the 90-day mark, but the most recent buy on 2025-10-08 underperformed with -23.0% over 90 days. The timing context is notable given the stock is -54.6% from its 52-week high and +39.3% over the last 30 days, suggesting he is buying into recent momentum. Additionally, 3 other insiders have purchased within the past 14 days, forming a cluster buy pattern that may signal coordinated conviction around current valuation levels.

Director Maggiore buys 23,682 shares of ZIVO at $12.01; prior 5 same-ticker buys all posted positive 90-day returns (up to +760.0%).

Maggiore Christopher D., a director of Zivo Bioscience, purchased 23,682 shares at $12.01 on 2025-10-08, expanding his holdings by 4.8% to 517,526 shares. This buy occurs in a context of mixed signals: the stock trades at $13.01 currently—41.1% below its 52-week high of $22.10—but Maggiore's five prior open-market purchases at this same ticker all generated positive 90-day returns, ranging from +50.3% to +760.0%, indicating consistent timing accuracy at ZIVO. The company remains unprofitable (latest quarter net income of $-1,640,232.00) despite strong annualized revenue growth of +468.6%, placing the transaction in tension between fundamental headwinds and an insider's historical success in reading entry points at this ticker.

Director Maggiore buys 31,336 shares of ZIVO at $8.34; holds 498,443 shares post-transaction (+6.7%)

Christopher D. Maggiore, a director, purchased 31,336 shares of Zivo Bioscience at $8.34 on 2024-08-22, expanding his holdings to 498,443 shares—a 6.7% increase. This marks his fifth open-market acquisition at ZIVO in less than three months (prior buys on 2024-07-26, 2024-06-12, 2023-12-29, and 2023-12-13), signaling sustained insider accumulation at the same company. At ZIVO specifically, his two prior measurable buys showed strong 90-day returns: +496.2% (2023-12-29) and +760.0% (2023-12-13), both well-timed acquisitions where the stock rallied post-purchase. However, the company remains unprofitable with net income of $-8,236,368.00 for its latest full fiscal year and zero revenue in the most recent quarter, indicating material operational distress or development-stage status. The current price of $8.25 is 28.4% below the 52-week high, providing context for recent entry points, though investors should weigh the director's historical execution success at this ticker against the company's fundamental weakness.

Director Maggiore buys 2,080 shares of ZIVO at $8.05; track record shows 2 of 2 prior same-ticker buys were well-timed with 90d gains of +669.2% and +760.0%.

Maggiore Christopher D., a director at Zivo Bioscience, purchased 2,080 shares at $8.05 on 2024-07-26, increasing his holdings to 467,107 shares. The significance of this purchase is reinforced by his prior transaction history at ZIVO: his two prior same-ticker buys (on 2023-12-13 and 2023-12-29) both proved well-timed over the 90-day window, generating returns of +760.0% and +496.2% respectively, with a 100% win rate on measurable outcomes. This represents the third buy at this ticker in seven months, signaling repeated director conviction despite the company's ongoing unprofitability (net income of $-1,278,486.00 for the most recent period) and depressed share price 33.0% below the 52-week high. The pattern of disciplined, repeated accumulation at a loss-making micro-cap warrants investor attention to any upcoming catalysts or strategic developments.